Christopher Rex
Fondatore presso Afraxis, Inc.
Profilo
Christopher Rex is the founder of Afraxis, Inc. which was founded in 2010, where he holds the title of Chief Scientific Officer.
He was also a Program Director at T123 LLC from 2018 to 2021.
Dr. Rex received his doctorate from the University of California, Irvine in 2008 and his undergraduate degree from the University of California, Santa Barbara in 2002.
Posizioni attive di Christopher Rex
| Società | Posizione | Inizio |
|---|---|---|
Afraxis, Inc.
 Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Fondatore | 01/01/2010 |
Precedenti posizioni note di Christopher Rex
| Società | Posizione | Fine |
|---|---|---|
T123 LLC
 T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California. | Direttore/Membro del Consiglio | 01/04/2021 |
Formazione di Christopher Rex
| University of California, Irvine | Doctorate Degree |
| University of California, Santa Barbara | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Health Technology |
T123 LLC
T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California. | Finance |
- Borsa valori
- Insiders
- Christopher Rex
